In this webinar, we ask ‘Why have generative chemistry methods been unable to redefine modern drug discovery and compound idea generation?’ In this session we shed light on a typical shortcoming of generative methods.
Joe McDonald, Chief Data Officer at Odyssey Therapeutics, Peter Hunt, Director of Computational Chemistry at Optibrium Ltd and Ed Champness, CSO at Optibrium discuss experiences using generative methods and their ideas on how to close the gaps.
See how Optibrium’s Inspyra iteratively learns priorities for your projects, generating compound ideas tailored to your needs. Via your interactions, Inspyra guides generative chemistry and multi-parameter optimisation capabilities. It combines the explorative power of generative methods with your expert knowledge, helping you identify better compounds faster.
Other webinars you may be interested in
StarDrop 8 Is Here: Pioneering Collaboration in Drug Discovery
Science shouldn’t be a solo act. And now, with StarDrop 8 available and ready to use, it never has to be. Learn how you…
Building better QSAR models: A new framework for consistent performance across diverse prediction tasks
Accurate QSAR models lead to more efficient and cost-effective molecular discovery. Better predictions enable you to prioritise the optimal compounds…
